AI Terminal
Dr. Martens PLC
Delisting Announcement • Nov 2, 2023
5055_rns_2023-11-02_cb7431ad-9386-4df6-992d-c2d42d8a4b06.html
Delisting Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0933S
Dr. Martens PLC
02 November 2023
2 November 2023
Dr. Martens plc (the "Company")
Block Listing application
The Company announces today that application has been made to the FCA and to the London Stock Exchange for admission to (i) the Official List and (ii) to trading on the London Stock Exchange's main market for a block listing of securities in respect of a total of 3,500,000 ordinary shares of GBP 0.01 each (the "Ordinary Shares") in the Company. It is expected that admission will become effective on 3 November 2023.
The Ordinary Shares are being reserved under a block listing and will be issued as and when required under the Company's employee share plans.
When issued the Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Enquiries:
Investors and analysts
Bethany Barnes, Director of Investor Relations
Gill Hammond, Communications Director
Paul Rolling, Assistant Company Secretary
About Dr. Martens plc
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ALSBBBFTMTBMBJJ